Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma
| Title: | Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma |
|---|---|
| Authors: | Farinati F.; Vitale A.; Spolverato G.; Pawlik T. M.; Huo T. -L.; Lee Y. -H.; Frigo A. C.; Giacomin A.; Giannini E. G.; Ciccarese F.; Piscaglia F.; Rapaccini G. L.; Di Marco M.; Caturelli E.; Zoli M.; Borzio F.; Cabibbo G.; Felder M.; Sacco R.; Morisco F.; Biasini E.; Foschi F. G.; Gasbarrini A.; Svegliati Baroni G.; Virdone R.; Masotto A.; Trevisani F.; Cillo U.; Biselli M.; Bolondi L.; Bucci L.; Cucchetti A.; Garuti F.; Gramenzi A.; Lenzi B.; Magalotti D.; Pecorelli A.; Serra C.; Venerandi L.; Gazzola A.; Murer F.; Pozzan C.; Vanin V.; Del Poggio P.; Olmi S.; Balsamo C.; Vavassori E.; Benvegnu L.; Capelli A.; Golfieri R.; Mosconi C.; Renzulli M.; Bosco G.; Roselli P.; Dell'Isola S.; Ialungo A. M.; Rastrelli E.; Moscatelli A.; Pellegatta G.; Picciotto A.; Savarino V.; Barcellona M. R.; Camma C.; Costantino A.; Affronti A.; Mega A.; Rinninella E.; Mismas V.; Dall'Aglio A. C.; Feletti V.; Lanzi A.; Mirici Cappa F.; Neri E.; Stefanini G. F.; Tamberi S.; Missale G.; Porro E.; Guarino M.; Schiada L.; Cuttone F.; Chiaramonte M.; Marchetti F.; Valerio M. |
| Contributors: | F. Farinati; A. Vitale; G. Spolverato; T.M. Pawlik; T.-. Huo; Y.-. Lee; A.C. Frigo; A. Giacomin; E.G. Giannini; F. Ciccarese; F. Piscaglia; G.L. Rapaccini; M. Di Marco; E. Caturelli; M. Zoli; F. Borzio; G. Cabibbo; M. Felder; R. Sacco; F. Morisco; E. Biasini; F.G. Foschi; A. Gasbarrini; G. Svegliati Baroni; R. Virdone; A. Masotto; F. Trevisani; U. Cillo; M. Biselli; L. Bolondi; L. Bucci; A. Cucchetti; F. Garuti; A. Gramenzi; B. Lenzi; D. Magalotti; A. Pecorelli; C. Serra; L. Venerandi; A. Gazzola; F. Murer; C. Pozzan; V. Vanin; P. Del Poggio; S. Olmi; C. Balsamo; E. Vavassori; L. Benvegnu; A. Capelli; R. Golfieri; C. Mosconi; M. Renzulli; G. Bosco; P. Roselli; S. Dell'Isola; A.M. Ialungo; E. Rastrelli; A. Moscatelli; G. Pellegatta; A. Picciotto; V. Savarino; M.R. Barcellona; C. Camma; A. Costantino; A. Affronti; A. Mega; E. Rinninella; V. Misma; A.C. Dall'Aglio; V. Feletti; A. Lanzi; F. Mirici Cappa; E. Neri; G.F. Stefanini; S. Tamberi; G. Missale; E. Porro; M. Guarino; L. Schiada; F. Cuttone; M. Chiaramonte; F. Marchetti; M. Valerio |
| Publisher Information: | Public Library of Science |
| Publication Year: | 2016 |
| Collection: | The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| Subject Terms: | Settore MEDS-10/A - Gastroenterologia |
| Description: | Background: Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings: Prospective collected databases from Italy (training cohort, n = 3,628; internal validation cohort, n = 1,555) and Taiwan (external validation cohort, n = 2,651) were used to develop the ITA.LI.CA prognostic system. We first defined ITA.LI.CA stages (0, A, B1, B2, B3, C) using only tumor characteristics (largest tumor diameter, number of nodules, intra- and extrahepatic macroscopic vascular invasion, extrahepatic metastases). A parametric multivariable survival model was then used to calculate the relative prognostic value of ITA.LI.CA tumor stage, Eastern Cooperative Oncology Group (ECOG) performance status, Child–Pugh score (CPS), and alpha-fetoprotein (AFP) in predicting individual survival. Based on the model results, an ITA.LI.CA integrated prognostic score (from 0 to 13 points) was constructed, and its prognostic power compared with that of other integrated systems (BCLC, HKLC, MESIAH, CLIP, JIS). Median follow-up was 58 mo for Italian patients (interquartile range, 26–106 mo) and 39 mo for Taiwanese patients (interquartile range, 12–61 mo). The ITA.LI.CA integrated prognostic score showed optimal discrimination and calibration abilities in Italian patients. Observed median survival in the training and internal validation sets was 57 and 61 mo, respectively, in quartile 1 (ITA.LI.CA score ≤ 1), 43 and 38 mo in quartile 2 (ITA.LI.CA score 2–3), 23 and 23 mo in quartile 3 (ITA.LI.CA score 4–5), and 9 and 8 mo in quartile 4 (ITA.LI.CA score > 5). Observed and predicted median survival in the training and internal validation sets largely coincided. Although observed and predicted survival estimations were significantly lower (log-rank test, p < 0.001) in Italian than in Taiwanese patients, the ITA.LI.CA score maintained very high ... |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/27116206; info:eu-repo/semantics/altIdentifier/wos/WOS:000375096900017; volume:13; issue:4; firstpage:1; lastpage:18; numberofpages:18; journal:PLOS MEDICINE; https://hdl.handle.net/2434/1157795 |
| DOI: | 10.1371/journal.pmed.1002006 |
| Availability: | https://hdl.handle.net/2434/1157795; https://doi.org/10.1371/journal.pmed.1002006 |
| Rights: | info:eu-repo/semantics/openAccess |
| Accession Number: | edsbas.31866608 |
| Database: | BASE |